NCT00590473已完成不适用
Sacral Neuromodulation: Bilateral Placement vs. Unilateral Placement in Patients With Interstitial Cystitis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 2
- 主要终点
- To determine if bilateral sacral neuromodulation will reduce the patient's score on the Interstitial Cystitis Symptom and Problem Questionnaire by at least 25% when compared to unilateral sacral neuromodulation in patients with interstitial cystitis.
研究概览
简要总结
The hypothesis for this study is that bilateral sacral neuromodulation will improve symptoms of interstitial cystitis by at least 25% when compared to unilateral sacral neuromodulation as reported by patient's responses to the Interstitial Cystitis Symptom and Problem Indices.
This study will be a prospective randomized study comparing bilateral to unilateral sacral neuromodulation. The study population will include all patients diagnosed with interstitial cystitis, using the NIDDK criteria, having staged sacral neuromodulator stimulators placed at Hahnemann University Hospital.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 79 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of interstitial cystitis for at least 6 months.
- •At least 18yrs old and less than
- •Symptoms of urgency (>4 on the visual analog scale).
- •Symptoms of urinary frequency (>8 episodes/day as recorded on a voiding diary)
- •Symptoms of pelvic pain (>4 on the visual analog scale for pelvic pain).
- •Interstitial Cystitis refractory to more conservative treatments such as behavioral modification, dietary intervention, or medical therapy for at least 6 months.
- •Able to make medical decisions for herself.
- •Presence of either glomerulations of Hunner's ulcer on cystoscopic examination.
- •Participant must agree to use a medically acceptable method of contraception throughout the entire study period, and for 7 days after the study period. Medically acceptable methods of contraception include abstinence, birth control pills or patches, diaphragm with spermicide, IUD, condom with vaginal spermicide, surgical sterilization, post menopausal for at least 1 year, implants or injections, or vasectomized partner.
- •Must give written informed consent to participate in this study.
排除标准
- •Prior sacral neuromodulation.
- •Participant is currently pregnant or breastfeeding.
- •Urinary retention (defined by post void residual greater than 100cc).
- •Neurologic deficit.
- •Need for future MRI surveillance.
- •Involved in any study within the past thirty days or currently enrolled.
- •Presence of bladder or ureteral calculi.
- •Active genital herpes.
- •Uterine, cervical, vaginal, or urethral cancer.
- •Urethral diverticulum.
- •Cyclophosphamide cystitis.
- •Vaginitis.
- •Tuberculous cystitis.
- •Foreign body within the bladder (indwelling catheter- foley or suprapubic tube, or ureteral stent).
- •An employee or a relative of an employee of Medtronic Inc. or The Pelvic and Sexual Health Institute.
- •Bladder capacity greater than 350 cc while awake during cystometrogram.
- •Duration of symptoms of less than 6 months.
- •Detrusor overactivity on cystometrogram.
- •Absence of nocturia, defined by greater than 2 voids per sleeping hours.
- •Urinary symptoms relieved by either antimicrobials, antiseptics, anticholinergics, or antispasmodics.
- •Urinary frequency of less than 8 voids per day.
- •Diagnosis of bacterial cystitis or prostatitis within the past 3 months.
- •Radiation cystitis.
- •Benign or malignant bladder tumors.
- •Age less than 18 or greater than
- •Participant is currently receiving or has received pelvic radiation.
- •Participant is diagnosed with cancer within the past 5 years prior to the start of the study.
- •Participant has a history of alcohol or substance abuse within the past 5 years prior to the start of the study.
- •Severe or uncontrolled diabetes or diabetes with peripheral nerve involvement.
- •Patients with implanted electrical devices (cardiac pacemakers or defibrillators).
- •Patients on anticoagulation therapy.
- •Planned future exposure to diathermy, microwave, or RF energy.
结局指标
主要结局
To determine if bilateral sacral neuromodulation will reduce the patient's score on the Interstitial Cystitis Symptom and Problem Questionnaire by at least 25% when compared to unilateral sacral neuromodulation in patients with interstitial cystitis.
时间窗: Post-op, at 6 weeks and at 3 months post-surgery
次要结局
- To determine if bilateral sacral neuromodulation will improve the patient's voiding diary defined as reduction in urinary frequency by 25% from baseline when compared to unilateral sacral neuromodulation in patients with interstitial cystitis(Post-op, at 6 weeks and 3 months post-surgery)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Sacral Neuromodulation Test With Bilateral First Stage Tined Lead Procedure in Patients With Non-obstructive Urinary Retention: A Pilot StudyUrinary RetentionNCT00878176Maastricht University Medical Center12
已完成
不适用
Secondary Bilateral Sacral Nerve Stimulation in Overactive Bladder PatientsBladder HyperactivityNCT01960270University Hospital, Rouen34
招募中
不适用
Sacral Neuromodulation for Neurogenic Lower Urinary Tract, Bowel and Sexual DysfunctionNeurogenic Dysfunction of the Urinary BladderSacral NeuromodulationBowel DysfunctionQuality of LifeMultiple SclerosisSexual DysfunctionNCT05380856Odense University Hospital60
已完成
3 期
Phase I Deep Brain Stimulation (DBS) vs. Best Medical Therapy (BMT) TrialParkinson's DiseaseNCT00056563US Department of Veterans Affairs255
Enrolling By Invitation
不适用
Sacral Neuromodulation in Neurogenic PatientsNeurogenic BowelUrge IncontinenceRetention, UrinaryOveractive BladderNeurogenic BladderFecal IncontinenceNCT05688644Omri Schwarztuch Gildor100